Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2017, Article ID 4895736, 5 pages
https://doi.org/10.1155/2017/4895736
Case Report

Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction

Liver Transplant Unit, Auckland City Hospital, 2 Park Road, Grafton, Auckland 1023, New Zealand

Correspondence should be addressed to Shih Yea Sylvia Wu; moc.liamg@9201leunammi

Received 3 February 2017; Accepted 12 March 2017; Published 20 March 2017

Academic Editor: Marco Sebastiani

Copyright © 2017 Shih Yea Sylvia Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organisation, “Hepatitis C,” http://www.who.int/mediacentre/factsheets/fs164/en/.
  2. R. Lozano, M. Naghavi, K. Foreman et al., “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010,” The Lancet, vol. 380, pp. 2095–2128, 1990. View at Google Scholar
  3. E. Gane, C. Stedman, C. Brunton et al., “Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand,” New Zealand Medical Journal, vol. 127, no. 1407, pp. 61–74, 2014. View at Google Scholar · View at Scopus
  4. R. T. Chung, G. L. Davis, D. M. Jensen et al., “Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus,” Hepatology, vol. 62, no. 3, pp. 932–954, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. L. M. Hagan and R. F. Schinazi, “Best strategies for global HCV eradication,” Liver International, vol. 33, no. 1, pp. 68–79, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. P. Manns, J. G. McHutchison, S. C. Gordon et al., “Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” The Lancet, vol. 358, no. 9286, pp. 958–965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Bansal, A. K. Singal, B. M. McGuire, and B. S. Anand, “Impact of all oral anti-hepatitis C virus therapy: a meta-analysis,” World Journal of Hepatology, vol. 7, no. 5, pp. 806–813, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. J. J. Feld, K. V. Kowdley, E. Coakley et al., “Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin,” New England Journal of Medicine, vol. 370, no. 17, pp. 1594–1603, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Ferenci, D. Bernstein, J. Lalezari et al., “ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV,” New England Journal of Medicine, vol. 370, no. 21, pp. 1983–1992, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Poordad, C. Hezode, R. Trinh et al., “ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis,” New England Journal of Medicine, vol. 370, no. 21, pp. 1973–1982, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Zeuzem, I. M. Jacobson, T. Baykal et al., “Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin,” The New England Journal of Medicine, vol. 370, no. 17, pp. 1604–1614, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. AbbVie Ltd, “VIEKIRA PAK data sheet,” August 2016, http://www.medsafe.govt.nz/profs/datasheet/v/viekiraPaktab.pdf.
  13. M. Schwaiblmair, W. Behr, T. Haeckel, B. Märkl, W. Foerg, and T. Berghaus, “Drug induced interstitial lung disease,” Open Respiratory Medicine Journal, vol. 6, no. 1, pp. 63–74, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. J. Erasmus, H. Page McAdams, and S. E. Rossi, “Drug-induced lung injury,” Seminars in Roentgenology, vol. 37, no. 1, pp. 72–81, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Wolkove, “Amiodarone pulmonary toxicity,” Canadian Respiratory Journal, vol. 16, no. 2, pp. 43–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Matsuno, “Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches,” Respiratory Research, vol. 13, article 39, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Lubel, “Excellent SVR12 rates with VIEKIRA PAK in a real-world cohort of HCV Genotype 1 patients predominantly with cirrhosis—the Australian REV1TAL Study,” AASLD LiverLearning, 143851, 2016. View at Google Scholar